Bladder cancer

NEW --- Targeted therapies for metastatic UCa in special populations

Earn accreditation points

Finish 5 case(s) answer 10 question(s) and Earn 1 credit.

Continue
Objectif pédagogique: Get familiar with the current indications of immunotherapy and antibody-drug conjugates for metastatic urothelial carcinoma (UCa). Learn to identify patient characteristics that impact the appropriateness of immunotherapy and antibody-drug conjugates.
Spécialité: Medical oncology, urology, clinical oncology, (radiation oncology)
Public cible: Specialists (CME: basic, intermediate), Residents (senior)
Dernière mise à jour: May 2024
Contexte:

Regulatory approval status of drugs for metastatic UCa (status: 7 May 2024)

ChT: chemotherapy; CPS: combined positive score